Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 201 to 236 of 236 results for dementia

  1. What is the effectiveness of statin therapy in older people?

    statins in preventing or promoting other chronic diseases of ageing such as dementia, Parkinson's disease, or age-related macular...

  2. Interventions for preventing falls in older inpatients:- How can falls among older inpatients be prevented? Which patients are most likely to benefit from falls prevention interventions, and does the effectiveness of interventions relate to the patient's length of stay?

    nor has their effectiveness in specific subgroups such as patients with dementia. High-quality randomised controlled trials conducted in...

  3. Challenging behaviour and learning disabilities: prevention and interventions for people with learning disabilities whose behaviour challenges (NG11)

    This guideline covers interventions and support for children, young people and adults with a learning disability and behaviour that challenges. It highlights the importance of understanding the cause of behaviour that challenges, and performing thorough assessments so that steps can be taken to help people change their behaviour and improve their quality of life. The guideline also covers support and intervention for family members or carers.

  4. A framework for Commissioning with NICE Guidance & related Quality Standards

    consisted of representatives from the CCG, CSU and NICE. Commissioning dementia services was identified as a strategic priority for the...

  5. Improving services by focussing on what works: developing NICE learning in a Local Authority

    guidance to support workforce training and development - Older adults and dementia A number of participants said that they had found the...

  6. Rifaximin for preventing episodes of overt hepatic encephalopathy (TA337)

    Evidence-based recommendations on rifaximin (Targaxan) for preventing episodes of hepatic encephalopathy in adults.

  7. Physical activity: for NHS staff, patients and carers (QS84)

    This quality standard covers encouraging physical activity in people of all ages who are in contact with the NHS, including staff, patients and carers. It describes high-quality care in priority areas for improvement.

  8. Management of aggression, agitation and behavioural disturbances in dementia: carbamazepine (ESUOM40)

    This evidence summary has been updated and replaced by NICE guideline NG97.

  9. Management of aggression, agitation and behavioural disturbances in dementia: valproate preparations (ESUOM41)

    This evidence summary has been updated and replaced by NICE guideline NG97.

  10. Excess winter deaths and illness and the health risks associated with cold homes (NG6)

    This guideline covers reducing the health risks (including preventable deaths) associated with living in a cold home. It aims to improve the health and wellbeing of people vulnerable to the cold. Improving the temperature in homes, by improving energy efficiency, may also help reduce unnecessary fuel consumption.

  11. Dual‑chamber pacemakers for symptomatic bradycardia due to sick sinus syndrome without atrioventricular block (TA324)

    Evidence-based recommendations on dual-chamber pacemakers for treating symptomatic bradycardia caused by sick sinus syndrome without atrioventricular block.

  12. Oral health: local authorities and partners (PH55)

    This guideline covers improving oral health by developing and implementing a strategy that meets the needs of people in the local community. It aims to promote and protect people’s oral health by improving their diet and oral hygiene, and by encouraging them to visit the dentist regularly.

  13. Schizophrenia: lurasidone (ESNM48)

    Summary of the evidence on lurasidone (Latuda) for schizophrenia in adults aged 18 and over to inform local NHS planning and decision-making

  14. Interim methods guide for developing good practice guidance (PMG15)

    Interim methods guide for developing good practice guidance

  15. Delirium in adults (QS63)

    This quality standard covers the prevention, diagnosis and management of delirium in adults (aged 18 and over) in hospital or long-term care settings (such as residential care or nursing homes). It describes high-quality care in priority areas for improvement.

  16. Safe staffing for nursing in adult inpatient wards in acute hospitals (SG1)

    This guideline covers organisational and managerial approaches to safe nurse staffing of inpatient wards for people aged 18 and over in acute hospitals. It aims to ensure that patients receive the nursing care they need, regardless of the ward to which they are allocated, the time of the day, or the day of the week.

  17. Insertion of a magnetic bead band for faecal incontinence (IPG483)

    Evidence-based recommendations on insertion of a magnetic-bead band for faecal incontinence. This involves placing a ring of magnetic beads into a tunnel made around the anus to prevent incontinence.

  18. Difficult-to-treat scabies: oral ivermectin (ESUOM29)

    Summary of the evidence on oral ivermectin for treating difficult-to-treat scabies to inform local NHS planning and decision-making

  19. Mental wellbeing of older people in care homes (QS50)

    This quality standard covers the mental wellbeing of older people (aged 65 and over) receiving care in care homes (including residential and nursing accommodation, day care and respite care). It focuses on support for people to improve their mental wellbeing so that they can stay as well and independent as possible. It describes high-quality care in priority areas for improvement.

  20. Dementia: target organ damage (all patients) (IND118)

    This indicator covers the percentage of patients with dementia (diagnosed on or after 1 April 2014) with a record of FBC, calcium, glucose, renal and liver function, thyroid function tests, serum vitamin B12 and folate levels recorded up to 12 months before entering on to the register. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM72

  21. Dementia: independence and wellbeing (QS30)

    This quality standard has been updated and replaced by NICE quality standard 184

  22. What should NICE take into account when developing social care guidance?

    What should NICE take into account when developing social care guidance?

  23. Have your say on NICE's social care work

    The Department of Health has launched a 12 week consultation to gather views on the topics for NICE's new quality standards and guidance for social care.

  24. How NICE can help Clinical Commissioning Groups deliver high quality care

    Find out about the range of NICE products that can help Clinical Commissioning Groups deliver high quality care.

  25. Dementia: support in health and social care (QS1)

    This quality standard has been updated and replaced by NICE quality standard 184

  26. Lumbar infusion test for the investigation of normal pressure hydrocephalus (IPG263)

    Evidence-based recommendations on the lumbar infusion test for the investigation of normal pressure hydrocephalus. This involves inserting a lumbar needle into the spinal sac, recording the pressure of the CSF as fluid is infused into the sac.

  27. Dementia: supporting people with dementia and their carers in health and social care (CG42)

    This guidance has been updated and replaced by NICE guideline NG97.

  28. Prevention of dementia

    Awaiting development [GID-QS10109] Expected publication date: TBC

  29. DHT pilot: DECODE decision support system for the identification of dementia (Discontinued)

    Discontinued [GID-MT536]

  30. New pharmaceutical treatments for non-Alzheimer dementias [ID380]

    Discontinued [GID-TAG369]

  31. Aducanumab for treating mild cognitive impairment and mild dementia caused by Alzheimer's disease [ID3763]

    Discontinued [GID-TA10739]

  32. Dementia

    All NICE products on dementia. Includes any guidance and quality standards.

  33. Donanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6222]

    In development [GID-TA11221] Expected publication date: 11 September 2024

  34. Lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID4043]

    In development [GID-TA11220] Expected publication date: TBC

  35. Hydromethylthionine mesylate for treating mild cognitive impairment or mild or moderate dementia caused by Alzheimer's disease ID6343

    In development [GID-TA11379] Expected publication date: TBC